Addiction Treatment Services

Addiction is a chronic disease, which causes individuals to seek “reward” from substance-use or other activities whether or not they may cause harm. Addiction treatment has been in the spotlight as payers, policymakers, and health systems struggle to address the opioid crisis and increasing substance-related mortality rates. As a result, the addiction treatment market is shifting—there is expanded coverage for residential treatment, a push towards greater integration and care coordination, and new competitors entering the market—creating new challenges and opportunities for organizations working in addiction treatment.

Latest Resources

• 17% Of Formerly Homeless Veterans With Opioid Use Disorder Received MOUD Within One Year Of Supportive Housing Placement
• SAMHSA Updates MOUD Guidance, Says Medication-Only Opioid Treatment Models Are Insufficient
• For Integration Success, Digital Anyone?
• SAMHSA Dear Colleague Letter: Updated Guidance On Medication Assisted Treatment/Medication For Opioid Use Disorder
• Breaking Down Silos: How One State Achieved 98% Faster Referral Response With Integrated Data & Coordination Tools
• DEA Reschedules FDA-Approved & State-Licensed Medical Marijuana Products; Hearing Set On Broader Marijuana Reclassification
• Community Healthlink In Massachusetts Prepares Program Transitions Ahead Of Closure
• CaredFor Launches Post-Discharge Measurement-Based Care Platform For Addiction Treatment Provider Organizations
• Finding ROI In MOUD
• Notice Of Hearing On Proposed Rulemaking: Schedules Of Controlled Substances: Rescheduling Of Marijuana
• Crafting Crisis
• One-Third Of Outpatient Behavioral Health Facilities Offer Programs Tailored For Older Adults
• Youth Cannabis Use Associated With Slower Cognitive Development & Reduced Gains In Memory, Attention & Processing Speed
• Clark County Opens Crisis Stabilization Center In Southern Nevada
• SAMHSA Prohibits Use Of Grant Funding For Fentanyl Test Strips & Overdose Hotlines In Updated Guidance

See All

GLP-1 Medications Linked To 15%–20% Lower Risk Of Substance Use Disorders In Veterans With Type 2 Diabetes

Researchers from the Veterans Affairs St. Louis Health Care System found that veterans with type 2 diabetes who were prescribed glucagon-like peptide-1 receptor agonists (GLP-1s) had a lower risk of developing substance use disorders (SUDs) compared to those prescribed sodium-glucose cotransporter-2 (SGLT-2) inhibitors, according to a study published in The BMJ. The study was conducted to examine whether GLP-1 medications—originally developed to treat type 2 diabetes and increasingly used for weight management—are associated with differences… Read

• Medicaid Member Use Of MOUD Increases to 69% 
• Updated Funding Guidance For Grantees On Supplies & Services
• Behavioral Health Parity Gap Persists In 43 States
• Model Standards for Crisis Care Workers
• Findhelp & MiResource Partner To Improve Behavioral & Mental Health Care Access With Directory Accuracy

To sign-up for bi-weekly Mental Health alerts, you must be signed in to your account.